Location History:
- Galway, IE (2011)
- Doughiska, IE (2012)
Company Filing History:
Years Active: 2011-2012
Title: Innovations of Keith Gibbons: Pioneering Aerosol Therapy
Introduction
Keith Gibbons, a prominent inventor based in Doughiska, Ireland, has made significant contributions to the field of aerosol therapy. With two patents to his name, Gibbons is focused on improving the delivery of medicaments for patients suffering from pulmonary diseases.
Latest Patents
Gibbons' latest patents showcase innovative methods and systems for operating an aerosol generator. One patent details a system that enables intermittent delivery of aerosolized medicaments, comprising an aerosol generator, a controller, and a conduit. This system is designed to effectively aerosolize a medicament based on the physiological characteristics of the patient. Another patent focuses on treating patients with pulmonary diseases by delivering aerosolized medicaments through a ventilator circuit. The method involves switching the patient off a ventilator and administering a nebulized aerosol containing specific quantities of medicament, such as amikacin mixed with a pH-adjusted aqueous solution.
Career Highlights
Keith Gibbons works with Novartis AG, a leading global healthcare company. His work primarily focuses on improving therapeutic techniques and enhancing patient care through innovative aerosol delivery systems. Gibbons remains committed to the advancement of medical technologies that benefit patients.
Collaborations
Throughout his career, Gibbons has collaborated with notable colleagues, including James B. Fink and John Sylvester Power. These partnerships have fostered a collaborative environment that encourages the development and optimization of innovative therapeutic solutions.
Conclusion
As an inventor, Keith Gibbons is at the forefront of aerosol therapy advancements. His contributions not only highlight his inventive prowess but also reflect a dedication to improving the lives of individuals with pulmonary conditions. With ongoing research and development, Gibbons continues to pave the way for breakthroughs in inhalation therapy and patient care.